Advertisement

Topics

Novartis Receives EU Approval for First-Line Use of Zykadia

14:41 EDT 30 Jun 2017 | PharmPro

Novartis receives EU approval for first-line use of Zykadia in ALK-positive advanced non-small cell lung cancer (NSCLC). A benefit also was seen in patients with brain metastases.
Contributed Author: 
Novartis Pharmaceuticals Corp.
Topics: 

Original Article: Novartis Receives EU Approval for First-Line Use of Zykadia

NEXT ARTICLE

More From BioPortfolio on "Novartis Receives EU Approval for First-Line Use of Zykadia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...